Literature DB >> 27399351

Endothelial Dysfunction as a Link Between Cardiovascular Risk Factors and Peripheral Neuropathy in Diabetes.

Matthieu Roustit1, Jordan Loader1, Carly Deusenbery1, Dimitrios Baltzis1, Aristidis Veves1.   

Abstract

CONTEXT: Cardiovascular risk factors are well-known predictors of the development of diabetic peripheral neuropathy (DPN), which has traditionally been considered as a manifestation of diabetes-associated microangiopathy. Because endothelial dysfunction is strongly associated with all cardiovascular risk factors, we hypothesized that it may be a link between cardiovascular risk factors and DPN.
OBJECTIVE: The primary objective of this study was to test whether endothelial dysfunction is a predictor of DPN. DESIGN AND
SETTING: This is a cross-sectional analysis of a cohort composed of patients followed at the Microcirculatory Laboratory, Beth Israel Deaconess Medical Center. PATIENTS: Participants with diabetes without DPN (n = 192) and with DPN (n = 166), subjects with prediabetes (n = 75), and nondiabetic controls (n = 59) were included.
INTERVENTIONS: Endothelial function was assessed with flow-mediated dilation (FMD) of the brachial artery. Inflammatory cytokines and biomarkers of endothelial function (soluble intercellular and vascular cell adhesion molecules) were quantified using a multiplex bead-based immunoassay. Neurological assessment included the neuropathy disability score (NDS). MAIN OUTCOME MEASURE: The relationship between FMD and NDS assessed using multiple linear regression.
RESULTS: In addition to already known risk factors of DPN, FMD was strongly associated with NDS (β = -0.24; P < .001). Sensitivity analysis that removed FMD from the model provided similar results for soluble intercellular cell adhesion molecule-1, another biomarker of endothelial function. Confirmatory factor analysis further showed that endothelial dysfunction is a significant mediator between glycosylated hemoglobin and diabetes duration and diabetic complications.
CONCLUSIONS: This study shows that endothelial dysfunction occurs early in the pathophysiology of diabetes and is a link between cardiovascular risk factors and DPN.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27399351      PMCID: PMC5010566          DOI: 10.1210/jc.2016-2030

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial.

Authors:  H Pham; D G Armstrong; C Harvey; L B Harkless; J M Giurini; A Veves
Journal:  Diabetes Care       Date:  2000-05       Impact factor: 19.112

2.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

3.  Early peripheral nerve abnormalities in impaired glucose tolerance.

Authors:  A Cappellari; L Airaghi; R Capra; A Ciammola; A Branchi; G Levi Minzi; N Bresolin
Journal:  Electromyogr Clin Neurophysiol       Date:  2005-06

Review 4.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

5.  Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes.

Authors:  A E Caballero; S Arora; R Saouaf; S C Lim; P Smakowski; J Y Park; G L King; F W LoGerfo; E S Horton; A Veves
Journal:  Diabetes       Date:  1999-09       Impact factor: 9.461

Review 6.  Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options.

Authors:  Aristidis Veves; Miroslav Backonja; Rayaz A Malik
Journal:  Pain Med       Date:  2008-09       Impact factor: 3.750

7.  Impaired Hedgehog signalling-induced endothelial dysfunction is sufficient to induce neuropathy: implication in diabetes.

Authors:  Candice Chapouly; Qinyu Yao; Soizic Vandierdonck; Frederic Larrieu-Lahargue; John N Mariani; Alain-Pierre Gadeau; Marie-Ange Renault
Journal:  Cardiovasc Res       Date:  2015-12-08       Impact factor: 10.787

8.  The evolving natural history of neurophysiologic function in patients with well-controlled diabetes.

Authors:  Christopher H Gibbons; Roy Freeman; Francisco Tecilazich; Thanh Dinh; Thomas E Lyons; Charalambos Gnardellis; Aristidis Veves
Journal:  J Peripher Nerv Syst       Date:  2013-06       Impact factor: 3.494

9.  Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors.

Authors:  Jackie Elliott; Solomon Tesfaye; Nish Chaturvedi; Rajiv A Gandhi; Lynda K Stevens; Celia Emery; John H Fuller
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 17.152

10.  Cardiovascular Risk Factors Increase the Risks of Diabetic Peripheral Neuropathy in Patients With Type 2 Diabetes Mellitus: The Taiwan Diabetes Study.

Authors:  Chun-Pai Yang; Cheng-Chieh Lin; Chia-Ing Li; Chiu-Shong Liu; Wen-Yuan Lin; Kai-Lin Hwang; Sing-Yu Yang; Hsuan-Ju Chen; Tsai-Chung Li
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more
  20 in total

1.  The association between perceived discrimination in midlife and peripheral neuropathy in a population-based cohort of women: the Study of Women's Health Across the Nation.

Authors:  Jennifer R Dusendang; Alexis N Reeves; Carrie A Karvonen-Gutierrez; William H Herman; Kelly R Ylitalo; Siobán D Harlow
Journal:  Ann Epidemiol       Date:  2019-07-27       Impact factor: 3.797

Review 2.  The Diabetic Foot as a Proxy for Cardiovascular Events and Mortality Review.

Authors:  Isa Dietrich; Gustavo Arruda Braga; Fernanda Gomes de Melo; Ana Carolina Calmon da Costa Silva Silva
Journal:  Curr Atheroscler Rep       Date:  2017-10-02       Impact factor: 5.113

3.  Diabetic Peripheral Neuropathy as a Predictor of Asymptomatic Myocardial Ischemia in Type 2 Diabetes Mellitus: A Cross-Sectional Study.

Authors:  Dimitrios Baltzis; Matthieu Roustit; Maria G Grammatikopoulou; Dimitrios Katsaboukas; Vassileios Athanasiou; Ioannis Iakovou; Aristidis Veves; Christos Manes; Maria-Christina Trakatelli
Journal:  Adv Ther       Date:  2016-08-23       Impact factor: 3.845

Review 4.  Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?

Authors:  M C Perez-Matos; M C Morales-Alvarez; C O Mendivil
Journal:  J Diabetes Res       Date:  2017-01-16       Impact factor: 4.011

5.  Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV.

Authors:  Ronald J Ellis; Monica Diaz; Ned Sacktor; Christina Marra; Ann C Collier; David B Clifford; Nigel Calcutt; Jerel A Fields; Robert K Heaton; Scott L Letendre
Journal:  Ann Clin Transl Neurol       Date:  2020-07-03       Impact factor: 4.511

6.  In patients with diabetic foot, improved left ventricular functions are detected by strain echocardiography after the diabetic foot treatment: A cross-sectional study.

Authors:  Derya Demirtas; Mehmet Kucukosmanoglu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 7.  Current Knowledge on the Vascular Effects of Menthol.

Authors:  Henrique Silva
Journal:  Front Physiol       Date:  2020-04-07       Impact factor: 4.566

Review 8.  Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease.

Authors:  William B Horton; Eugene J Barrett
Journal:  Endocr Rev       Date:  2021-01-28       Impact factor: 19.871

9.  Effects of alpha-lipoic acid treatment on serum progranulin levels and inflammatory markers in diabetic neuropathy.

Authors:  Bíborka Nádró; Hajnalka Lőrincz; Ágnes Molnár; Anita Szentpéteri; Eszter Zöld; Ildikó Seres; Dénes Páll; György Paragh; Péter Kempler; Mariann Harangi; Ferenc Sztanek
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

10.  Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.

Authors:  Phuong Tran Pham; Daiju Fukuda; Shusuke Yagi; Kenya Kusunose; Hirotsugu Yamada; Takeshi Soeki; Michio Shimabukuro; Masataka Sata
Journal:  Sci Rep       Date:  2019-08-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.